{"id":"iloprost-ventavis","safety":{"commonSideEffects":[{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Jaw pain"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Syncope"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iloprost mimics the natural prostacyclin (PGI2), a potent vasodilator and antiplatelet agent. By activating prostacyclin receptors (IP receptors), it increases intracellular cAMP levels, leading to relaxation of vascular smooth muscle, improved blood flow, and reduced platelet activation. This mechanism is particularly beneficial in pulmonary hypertension where it reduces pulmonary vascular resistance and improves hemodynamics.","oneSentence":"Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, causing vasodilation and inhibiting platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:37.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"},{"name":"Raynaud's phenomenon secondary to systemic sclerosis"}]},"trialDetails":[{"nctId":"NCT07498309","phase":"PHASE3","title":"Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-09","conditions":"Vaso-Occlusive Crises, Sickle Cell Disease","enrollment":144},{"nctId":"NCT07478094","phase":"","title":"Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-04-01","conditions":"Pulmonary Hypertension Due to Lung Diseases","enrollment":50},{"nctId":"NCT07450469","phase":"","title":"Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude","status":"NOT_YET_RECRUITING","sponsor":"Institute of Mountain Emergency Medicine","startDate":"2026-05","conditions":"Frostbite, Altitude, Field Physician Care","enrollment":10},{"nctId":"NCT07457762","phase":"NA","title":"AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-05-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":72},{"nctId":"NCT07424378","phase":"PHASE4","title":"Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-02","conditions":"Frostbite","enrollment":66},{"nctId":"NCT07356375","phase":"","title":"Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":32},{"nctId":"NCT07263958","phase":"NA","title":"Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-10","conditions":"Pulmnary Hypertension, COPD, Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia","enrollment":15},{"nctId":"NCT04583046","phase":"NA","title":"Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2020-11-02","conditions":"Lung Cancer (Including Metastatic Cancer), Pulmonary Infection","enrollment":78},{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","enrollment":14000},{"nctId":"NCT06319274","phase":"PHASE2","title":"Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure","status":"RECRUITING","sponsor":"Pär Johansson","startDate":"2024-04-15","conditions":"Acute Respiratory Failure, Endothelial Dysfunction, Pulmonary Infection","enrollment":450},{"nctId":"NCT03867097","phase":"PHASE2","title":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)","status":"COMPLETED","sponsor":"Civi Biopharma, Inc.","startDate":"2019-03-07","conditions":"Raynaud Phenomenon Secondary to Systemic Sclerosis","enrollment":34},{"nctId":"NCT04040322","phase":"PHASE3","title":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)","status":"COMPLETED","sponsor":"Civi Biopharma, Inc.","startDate":"2019-10-14","conditions":"Raynaud's Phenomenon Secondary to Systemic Sclerosis","enrollment":198},{"nctId":"NCT00709956","phase":"PHASE3","title":"Iloprost Power 15 in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-07","conditions":"Pulmonary Arterial Hypertension","enrollment":64},{"nctId":"NCT00302211","phase":"PHASE3","title":"The \"VISION\" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Actelion","startDate":"2006-02-01","conditions":"Pulmonary Hypertension","enrollment":67},{"nctId":"NCT00902603","phase":"","title":"Ventavis® Registry Protocol","status":"TERMINATED","sponsor":"Actelion","startDate":"2009-03","conditions":"Pulmonary Arterial Hypertension","enrollment":148},{"nctId":"NCT02170519","phase":"PHASE4","title":"Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide","status":"TERMINATED","sponsor":"Duke University","startDate":"2006-09","conditions":"Pulmonary Hypertension","enrollment":27},{"nctId":"NCT02825160","phase":"","title":"Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-08-01","conditions":"Hypertension, Pulmonary","enrollment":282},{"nctId":"NCT03788837","phase":"PHASE3","title":"ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-07-03","conditions":"Septic Shock Hyperdynamic","enrollment":240},{"nctId":"NCT05411107","phase":"PHASE2","title":"Oral Iloprost for the Prevention of Lung Cancer In Former Smokers","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-01","conditions":"Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease, Lung Carcinoma","enrollment":""},{"nctId":"NCT03903939","phase":"PHASE2","title":"Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure","status":"COMPLETED","sponsor":"Pär Johansson","startDate":"2019-05-22","conditions":"Multi Organ Failure","enrollment":228},{"nctId":"NCT04123444","phase":"PHASE2, PHASE3","title":"Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure","status":"COMPLETED","sponsor":"Jakob Stensballe, MD, PhD","startDate":"2019-10-30","conditions":"Septic Shock","enrollment":279},{"nctId":"NCT04420741","phase":"PHASE2","title":"Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure","status":"COMPLETED","sponsor":"Pär Johansson","startDate":"2020-06-15","conditions":"COVID-19, Respiratory Failure","enrollment":80},{"nctId":"NCT03044314","phase":"PHASE4","title":"Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension","status":"TERMINATED","sponsor":"Duke University","startDate":"2017-07-21","conditions":"Pulmonary Hypertension","enrollment":27},{"nctId":"NCT00561223","phase":"NA","title":"Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension","enrollment":10},{"nctId":"NCT02237183","phase":"PHASE1","title":"Iloprost in Preventing Lung Cancer in Former Smokers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-05","conditions":"Lung Carcinoma","enrollment":34},{"nctId":"NCT04543682","phase":"PHASE1, PHASE2","title":"A Clinical Trial Investigating Iloprost as Medication to Improve Bone Healing in Patients With Proximal Humeral Fracture","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2022-05-12","conditions":"Proximal Humeral Fracture","enrollment":30},{"nctId":"NCT02565030","phase":"","title":"Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-02","conditions":"Chronic Thromboembolic Pulmonary Hypertension, Idiopathic Pulmonary Arterial Hypertension","enrollment":1200},{"nctId":"NCT04445246","phase":"PHASE2","title":"Inhaled Iloprost for Suspected COVID-19 Respiratory Failure","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2020-05-23","conditions":"COVID-19, ARDS, Human, Hypoxemic Respiratory Failure","enrollment":40},{"nctId":"NCT05204784","phase":"NA","title":"Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Peter Korsten","startDate":"2022-02-28","conditions":"Systemic Sclerosis, Raynaud Phenomenon, Digital Ulcer","enrollment":30},{"nctId":"NCT03111212","phase":"PHASE3","title":"Iloprost in Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2019-06-25","conditions":"Respiratory Distress Syndrome, Adult","enrollment":150},{"nctId":"NCT04927039","phase":"NA","title":"Effects of Iloprost on Oxygenation During One-lung Ventilation in Supine-positioned Patients","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-06-24","conditions":"Mediastinal Mass","enrollment":60},{"nctId":"NCT03293407","phase":"","title":"Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-01","conditions":"Hypertension, Pulmonary","enrollment":31},{"nctId":"NCT02685618","phase":"PHASE2","title":"Endothelial Dysfunction in Resuscitated Cardiac Arrest","status":"COMPLETED","sponsor":"Pär Johansson","startDate":"2016-02","conditions":"Cardiac Arrest","enrollment":50},{"nctId":"NCT04598191","phase":"NA","title":"Effect of Intraoperative Iloprost Inhalant on Hemodynamic Stability in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-11-04","conditions":"Coronary Artery Occlusive Disease","enrollment":100},{"nctId":"NCT00084409","phase":"PHASE2","title":"Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2001-11","conditions":"Lung Cancer, Precancerous Condition","enrollment":152},{"nctId":"NCT02482402","phase":"PHASE2","title":"Iloprost for Bridging to Heart Transplantation in PH","status":"WITHDRAWN","sponsor":"Heidelberg University","startDate":"2015-02","conditions":"Chronic Left Ventricular Failure, Pulmonary Hypertension","enrollment":""},{"nctId":"NCT03620526","phase":"PHASE4","title":"Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-11-29","conditions":"Heart Failure With Normal Ejection Fraction","enrollment":34},{"nctId":"NCT03380325","phase":"NA","title":"The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2016-05-11","conditions":"Diabetes Mellitus, Type 2, Insulin Sensitivity/Resistance","enrollment":15},{"nctId":"NCT03936140","phase":"NA","title":"The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery","status":"COMPLETED","sponsor":"Seoul St. Mary's Hospital","startDate":"2018-01-04","conditions":"Lung Cancer","enrollment":72},{"nctId":"NCT01389271","phase":"","title":"Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-02-03","conditions":"Pulmonary Hypertension","enrollment":118},{"nctId":"NCT01971450","phase":"","title":"Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-11-21","conditions":"Hypertension, Pulmonary","enrollment":89},{"nctId":"NCT01054105","phase":"","title":"Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2010-10","conditions":"Pulmonary Arterial Hypertension","enrollment":73},{"nctId":"NCT03365479","phase":"NA","title":"Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2017-05-01","conditions":"Pulmonary Hypertension, Pulmonary Arterial Hypertension","enrollment":30},{"nctId":"NCT01774058","phase":"PHASE2","title":"The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation","status":"UNKNOWN","sponsor":"Prim PD Dr Afshin Assadian","startDate":"2012-10","conditions":"Diabetes, Arteriosclerosis, Peripheral Arterial Occlusive Disease","enrollment":100},{"nctId":"NCT02032836","phase":"PHASE1, PHASE2","title":"Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-10","conditions":"Pulmonary Arterial Hypertension","enrollment":27},{"nctId":"NCT01389206","phase":"","title":"Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":797},{"nctId":"NCT03610217","phase":"NA","title":"Pragmatic Clinical Trials in Scleroderma","status":"UNKNOWN","sponsor":"University of West London","startDate":"2018-10","conditions":"Scleroderma, Systemic, Sclerosis, Systemic","enrollment":400},{"nctId":"NCT02784899","phase":"NA","title":"Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2015-10-08","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT01894035","phase":"","title":"Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-09-23","conditions":"Pulmonary Hypertension","enrollment":13},{"nctId":"NCT03406988","phase":"NA","title":"Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers","status":"UNKNOWN","sponsor":"ASST Gaetano Pini-CTO","startDate":"2017-07-18","conditions":"Systemic Sclerosis, Digital Ulcer","enrollment":46},{"nctId":"NCT01469169","phase":"PHASE3","title":"Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06-19","conditions":"Hypertension, Pulmonary","enrollment":27},{"nctId":"NCT01781052","phase":"","title":"Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-09-11","conditions":"Pulmonary Arterial Hypertension","enrollment":17},{"nctId":"NCT01355380","phase":"","title":"Efficacy of Ventavis Used in Real-life Setting.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-08-05","conditions":"Pulmonary Arterial Hypertension","enrollment":55},{"nctId":"NCT02204852","phase":"PHASE2","title":"Co-administration of Iloprost and Eptifibatide in Septic Shock Patients","status":"COMPLETED","sponsor":"Sisse R. Ostrowski, MD PhD DMSc","startDate":"2014-09","conditions":"Septic Shock","enrollment":18},{"nctId":"NCT02826252","phase":"","title":"Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-15","conditions":"Hypertension, Pulmonary","enrollment":64},{"nctId":"NCT01941225","phase":"PHASE2","title":"Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2013-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT01598441","phase":"PHASE3","title":"Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD)","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-06","conditions":"Pulmonary Hypertension","enrollment":8},{"nctId":"NCT02490657","phase":"NA","title":"Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2015-07","conditions":"Video-assisted Thoracoscopic Surgery, Chronic Obstructive Pulmonary Disease","enrollment":44},{"nctId":"NCT01532544","phase":"PHASE2","title":"Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis","status":"TERMINATED","sponsor":"Thrombologic ApS","startDate":"2012-06","conditions":"Pneumonia","enrollment":5},{"nctId":"NCT01266265","phase":"","title":"Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2010-12","conditions":"Pulmonary Arterial Hypertension","enrollment":1333},{"nctId":"NCT01467791","phase":"","title":"Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2011-11","conditions":"Sarcoidosis, Pulmonary Hypertension","enrollment":300},{"nctId":"NCT01310751","phase":"PHASE2, PHASE3","title":"Study of Inhaled Iloprost in Pediatric Pulmonary Hypertension (PH) After Surgery","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-01","conditions":"Pulmonary Hypertension","enrollment":36},{"nctId":"NCT01437878","phase":"PHASE2","title":"Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Actelion","startDate":"2012-03","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension","enrollment":2},{"nctId":"NCT00709098","phase":"PHASE3","title":"Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-09","conditions":"Pulmonary Arterial Hypertension","enrollment":49},{"nctId":"NCT02238535","phase":"PHASE2","title":"Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2014-09","conditions":"Residual Pulmonary Hypertension","enrollment":60},{"nctId":"NCT00724321","phase":"PHASE1","title":"Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude","status":"WITHDRAWN","sponsor":"Loma Linda University","startDate":"2008-07","conditions":"Hypoxic Pulmonary Vasoconstriction","enrollment":""},{"nctId":"NCT01458041","phase":"","title":"Iloprost Therapy in Patients With Critical Limb Ischemia","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-08","conditions":"Peripheral Arterial Disease","enrollment":126},{"nctId":"NCT00250640","phase":"","title":"Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-04","conditions":"Hypertension, Pulmonary","enrollment":106},{"nctId":"NCT01319045","phase":"NA","title":"Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2011-06","conditions":"Pulmonary Arterial Hypertension, Congenital Heart Disease, Eisenmenger's Syndrome","enrollment":5},{"nctId":"NCT00981591","phase":"PHASE1, PHASE2","title":"Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients","status":"WITHDRAWN","sponsor":"Seattle Children's Hospital","startDate":"2009-09","conditions":"Pulmonary Hypertension, Neonatal Hypoxic Respiratory Failure, Persistent Pulmonary Hypertension of Newborn","enrollment":""},{"nctId":"NCT01468545","phase":"","title":"Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10","conditions":"Pulmonary Arterial Hypertension","enrollment":38},{"nctId":"NCT00409526","phase":"PHASE4","title":"Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2006-12","conditions":"Pulmonary Hypertension","enrollment":1},{"nctId":"NCT01712997","phase":"PHASE3","title":"Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2012-09","conditions":"Pulmonary Arterial Hypertension","enrollment":90},{"nctId":"NCT01836263","phase":"","title":"Prevention and Treatment of Digital Ulcers in Systemic Sclerosis","status":"UNKNOWN","sponsor":"marco matucci cerinic","startDate":"2013-04","conditions":"Systemic Sclerosis, Ulcer","enrollment":420},{"nctId":"NCT00403650","phase":"PHASE4","title":"Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2006-11","conditions":"Sarcoidosis, Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT00467896","phase":"PHASE2","title":"The \"Power 15 Study\": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting","status":"TERMINATED","sponsor":"Actelion","startDate":"2006-09","conditions":"Pulmonary Hypertension","enrollment":62},{"nctId":"NCT00723554","phase":"PHASE3","title":"Iloprost Power Disc-15 in Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Actelion","startDate":"2008-07","conditions":"Pulmonary Arterial Hypertension","enrollment":63},{"nctId":"NCT00741819","phase":"PHASE4","title":"Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2008-09","conditions":"Pulmonary Arterial Hypertension","enrollment":73},{"nctId":"NCT00927654","phase":"PHASE3","title":"Iloprost in High Risk Cardiac Surgical Patients","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2009-06","conditions":"Pulmonary Hypertension","enrollment":253},{"nctId":"NCT00235521","phase":"NA","title":"Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2005-05","conditions":"Pulmonary Hypertension","enrollment":15},{"nctId":"NCT01718288","phase":"PHASE4","title":"Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)","status":"COMPLETED","sponsor":"Fadoi Foundation, Italy","startDate":"2006-11","conditions":"Peripheral Arterial Disease","enrollment":150},{"nctId":"NCT00120380","phase":"PHASE4","title":"Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2004-09","conditions":"Hypertension","enrollment":40},{"nctId":"NCT01274481","phase":"PHASE1","title":"Iloprost Effects on Gas Exchange and Pulmonary Mechanics","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2011-03","conditions":"Acute Respiratory Distress Syndrome, Acute Lung Injury, Pulmonary Hypertension","enrollment":20},{"nctId":"NCT01649739","phase":"PHASE4","title":"Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2012-09","conditions":"Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT01320878","phase":"PHASE2","title":"Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2007-10","conditions":"Pulmonary Hypertension","enrollment":64},{"nctId":"NCT01549171","phase":"","title":"Enhanced Assisted Reproductive Technology Pregnancy Rate by Prostacyclin Analog (Iloprost)","status":"UNKNOWN","sponsor":"Fertility Specialists of Houston","startDate":"2010-01","conditions":"Pregnancy","enrollment":100},{"nctId":"NCT01082484","phase":"PHASE1, PHASE2","title":"Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2010-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT01209533","phase":"EARLY_PHASE1","title":"Inhaled Iloprost in Mild Asthma","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-09","conditions":"Asthma","enrollment":24},{"nctId":"NCT01383083","phase":"","title":"Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease","status":"UNKNOWN","sponsor":"Maryknoll Medical Center","startDate":"2010-11","conditions":"Pulmonary Arterial Hypertension","enrollment":42},{"nctId":"NCT01179776","phase":"PHASE1, PHASE2","title":"Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Thrombologic ApS","startDate":"2010-09","conditions":"Myocardial Infarct","enrollment":16},{"nctId":"NCT01062282","phase":"","title":"Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-07","conditions":"Pulmonary Hypertension","enrollment":41},{"nctId":"NCT00086463","phase":"PHASE2","title":"Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2004-06","conditions":"Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension","enrollment":60},{"nctId":"NCT01283958","phase":"","title":"The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2007-09","conditions":"Eisenmenger's Syndrome","enrollment":12},{"nctId":"NCT01116063","phase":"PHASE4","title":"Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)","status":"UNKNOWN","sponsor":"Carmel Medical Center","startDate":"2010-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":15},{"nctId":"NCT00185315","phase":"PHASE3","title":"Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2000-02","conditions":"Hypertension, Pulmonary","enrollment":71},{"nctId":"NCT00453414","phase":"PHASE2","title":"Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension","status":"WITHDRAWN","sponsor":"Actelion","startDate":"2006-07","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT00109681","phase":"PHASE2","title":"Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2005-04","conditions":"Pulmonary Fibrosis, Pulmonary Hypertension","enrollment":50},{"nctId":"NCT00414687","phase":"PHASE2","title":"Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"1998-07","conditions":"Hypertension, Pulmonary","enrollment":63},{"nctId":"NCT00882947","phase":"","title":"Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-02","conditions":"Primary Hypertension","enrollment":38},{"nctId":"NCT00216931","phase":"NA","title":"Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost","status":"WITHDRAWN","sponsor":"Lund University Hospital","startDate":"2006-05","conditions":"Persistent Pulmonary Hypertension, Respiratory Distress Syndrome","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ventavis"],"phase":"phase_3","status":"active","brandName":"Iloprost (Ventavis)","genericName":"Iloprost (Ventavis)","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, causing vasodilation and inhibiting platelet aggregation. Used for Pulmonary arterial hypertension (PAH), Raynaud's phenomenon secondary to systemic sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}